Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report)’s share price gapped up before the market opened on Monday . The stock had previously closed at $12.40, but opened at $13.75. Adlai Nortye shares last traded at $13.75, with a volume of 27,872 shares.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a report on Friday, January 12th.
Get Our Latest Stock Analysis on Adlai Nortye
Adlai Nortye Trading Down 13.6 %
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) by 128.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 35.21% of the company’s stock.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- What does consumer price index measure?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Best Stocks Under $10.00
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.